CXCR4/CXCL12 expression and signalling in kidney cancer

被引:218
作者
Schrader, AJ
Lechner, O
Templin, M
Dittmar, KEJ
Machtens, S
Mengel, M
Probst-Kepper, M
Franzke, A
Wollensak, T
Gatzlaff, P
Atzpodien, J
Buer, J
Lauber, J
机构
[1] German Res Ctr Biotechnol, Dept Cell Biol & Immunol, D-38124 Braunschweig, Germany
[2] Klinkum Braunschweig, Dept Visceral Surg & Urol, D-38126 Braunschweig, Germany
[3] Med Hochsch Hannover, Dept Urol, D-30623 Hannover, Germany
[4] Med Hochsch Hannover, Dept Pathol, D-30623 Hannover, Germany
[5] Med Hochsch Hannover, Dept Haematol & Oncol, D-30623 Hannover, Germany
[6] Med Hochsch Hannover, Inst Med Microbiol, D-30623 Hannover, Germany
关键词
CXCR4; CXCL12; kidney cancer; receptor signalling; functional genomics;
D O I
10.1038/sj.bjc.6600221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CXCL12 (SDF-1), a CXC-chemokine, and its specific receptor, CXCR4, have recently been shown to be involved in tumourgenesis, prolileration and angiogenesis. Therefore, we analysed CXCL12alpha/CXCR4 expression and function in four human kidney cancer cell lines (A-498, CAKI-1. CAKI-2, HA-7), 10 freshly harvested human tumour samples and corresponding normal kidney tissue. While none of the analysed tumour cell lines expressed CXCL12alpha, A-498 cells were found to express CXCR4, More importantly, real-time RT-PCR analysis of 10 tumour samples and respective adjacent normal kidney tissue disclosed a distinct and divergent downregulation of CXCL12alpha. and upregulation of CXCR-4 in primary tumour tissue. To prove that the CXCR4 protein is functionally active, rhCXCL12alpha was Investigated for its ability to induce changes of intracellular calcium levels in A-498 cells, Moreover, we used cDNA expression arrays to evaluate the biological influence or CXCL12alpha. Comparing gene expression profiles in rhCXCL12alpha stimulated vs unstimulated A-498 kidney cancer cells revealed specific regulation of 31 out of 1 176 genes tested on a selected human cancer array. with a prominent Stimulation of genes involved In cell-cycle regulation and apoptosis, The genetic changes reported here should provide new insights into the developmental paths leading to tumour progression and may also aid the design of new approaches to therapeutic Intervention, (C) 2002 Cancer Research UK.
引用
收藏
页码:1250 / 1256
页数:7
相关论文
共 36 条
  • [1] Begum NA, 1999, INT J ONCOL, V14, P927
  • [2] Loss of hIRH mRNA expression from premalignant adenomas and malignant cell lines
    Begum, NA
    Coker, A
    Shibuta, K
    Swanson, RS
    Chen, LB
    Mori, M
    Barnard, GF
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 229 (03) : 864 - 868
  • [3] KAI1, A METASTASIS SUPPRESSOR GENE FOR PROSTATE-CANCER ON HUMAN-CHROMOSOME 11P11.2
    DONG, JT
    LAMB, PW
    RINKERSCHAEFFER, CW
    VUKANOVIC, J
    ICHIKAWA, T
    ISAACS, JT
    BARRETT, JC
    [J]. SCIENCE, 1995, 268 (5212) : 884 - 886
  • [4] Chemokine receptor expression by human intestinal epithelial cells
    Dwinell, MB
    Eckmann, L
    Leopard, JD
    Varki, NM
    Kagnoff, MF
    [J]. GASTROENTEROLOGY, 1999, 117 (02) : 359 - 367
  • [5] Eisen MB, 1999, METHOD ENZYMOL, V303, P179
  • [6] Chemokine receptors and virus entry in the central nervous system
    Gabuzda, D
    Wang, JB
    [J]. JOURNAL OF NEUROVIROLOGY, 1999, 5 (06) : 643 - 658
  • [7] Guo XZ, 1996, CANCER RES, V56, P4876
  • [8] MOLECULAR-CLONING OF TPAR1, A GENE WHOSE EXPRESSION IS REPRESSED BY THE TUMOR PROMOTER 12-O-TETRADECANOYLPHORBOL 13-ACETATE (TPA)
    JIANG, W
    ZHOU, P
    KAHN, SM
    TOMITA, N
    JOHNSON, MD
    WEINSTEIN, IB
    [J]. EXPERIMENTAL CELL RESEARCH, 1994, 215 (02) : 284 - 293
  • [9] Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1
    Jo, DY
    Rafii, S
    Hamada, T
    Moore, MAS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 101 - 111
  • [10] Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells
    Jordan, NJ
    Kolios, G
    Abbot, SE
    Sinai, MA
    Thompson, DA
    Petraki, K
    Westwick, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (08) : 1061 - 1069